Abstract 1565
Background
Metabolic tumor volume(MTV) measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography(FDG PET/CT) was correlated with prognosis in various cancers. The aim of this study was to investigate the prognostic value of MTV in metastatic breast cancer (MBC).
Methods
We retrospectively reviewed 172 patients who underwent FDG PET/CT at diagnosis of MBC at a single center. MTV for the whole body tumor lesions were measured by FDG PET/CT. The prognostic significance of MTV and other clinicopathological variables for progression free survival (PFS) to the first line palliative treatment(1L-PFS) was assessed by Kaplan-Meier method and Cox proportional hazards regression analysis.
Results
Median age was 45 years (range 27-71). 76 patients had hormone receptor-positive(HR+)/human epidermal receptor-2 negative(HER2-) disease, 55 patients had HER2+ and 41 patients had triple negative breast cancer(TNBC). In the univariate analysis, TNBC subtype and higher MTV was associated with worse 1L-PFS. On multivariate analysis adjusted for age, presence of visceral metastases, and liver involvement, indepent predictive factors associated with decreased 1L-PFS were TNBC (HR 2.724 versus HR+/HER2 subtype, p = 0.002) and MTV (HR 1.165 with doubling of MTV, p = 0.001).
Conclusions
MTV, a volumetric parameter of FDG PET/CT, is an important independent prognostic factor for PFS to the first line palliative treatment, irrespective of tumor subtype, in patients with MBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y.H. Park: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Research grant / Funding (self): Eisai; Advisory / Consultancy, Research grant / Funding (self): Novartis; Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2376 - Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease
Presenter: Johannes Ettl
Session: Poster Display session 2
Resources:
Abstract
4874 - Complete Responses in Patients With 2nd-Line or Greater Metastatic Triple-Negative Breast Cancer (TNBC) Following First-in-Human Immunotherapy Combining NK and T Cell Activation with Off-the-Shelf High-Affinity CD16 NK Cell Line (haNK)
Presenter: Chaitali Nangia
Session: Poster Display session 2
Resources:
Abstract
4362 - Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)
Presenter: Aurelia Noske
Session: Poster Display session 2
Resources:
Abstract
4528 - Systemic Therapy in 2nd-Line Metastatic Triple Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy
Presenter: Peter Kaufman
Session: Poster Display session 2
Resources:
Abstract
4112 - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Presenter: Yang Chen
Session: Poster Display session 2
Resources:
Abstract
5699 - Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Joyce O’Shaughnessy
Session: Poster Display session 2
Resources:
Abstract
1931 - Maintenance Chemotherapy is effective in Patients with Metastatic Triple Negative Breast Cancer After First-line Platinum-based Chemotherapy
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract
4696 - Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to investigate symptom burden enrichment in Stage IV patients at an academic center
Presenter: Madeline Matthys
Session: Poster Display session 2
Resources:
Abstract
4582 - Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS
Presenter: Meghan Karuturi
Session: Poster Display session 2
Resources:
Abstract
3565 - Real-World 1-Year Survival Analysis of Patients with Metastatic Breast Cancer with Liver or Lung Metastasis Treated with Eribulin, Gemcitabine or Capecitabine
Presenter: Shayma Kazmi
Session: Poster Display session 2
Resources:
Abstract